Eloxx Pharmaceuticals Provides Pipeline and Financing Updates


First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations

Read more:
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Related Posts